3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Fluorouracil
17
Cisplatin
17
pembrolizumab
12
Radiotherapy
11
Oxaliplatin
10
Irinotecan
9
Paclitaxel
6
Leucovorin
6
Docetaxel
6
Carboplatin
6
Capecitabine
6
Neoadjuvant Therapy
5
Trastuzumab
4
Panitumumab
4
Gefitinib
4
Esophagectomy
4
Cyclophosphamide
4
Cetuximab
4
Surgical Procedures, Operative
3
Celecoxib
3
tegafur-gimeracil-oteracil
2
spartalizumab
2
sodium glycididazole
2
niraparib
2
fludarabine
2
S 1 (combination)
2
Plicamycin
2
Pemetrexed
2
Lapatinib
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Esophageal Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled